Prime Medicine (PRME) CFO Svetlana Makhni Receives 800,000-Share Award

What Happened

Makhni Svetlana Ni (Chief Financial Officer) received a derivative equity award on April 16, 2026 for 800,000 shares (reported as a grant, transaction code A). The award was recorded at $0.00 cash consideration — this is a grant of a vested/vesting right (an option or similar derivative), not an open-market purchase or sale.

Key Details

• Transaction date: 2026-04-16; Filing date: 2026-04-17 (timely filing).
• Transaction type/code: A (award/grant of a derivative security). Price reported: $0.00; aggregate cash paid: $0.
• Vesting: 25% of shares underlying the option vest on April 16, 2027; the balance vests monthly in equal installments over the following 36 months, subject to continued service (footnote F1).
• Shares owned after transaction: not specified in the provided summary — see the Form 4 for the reporter’s total holdings.
• No sale or exercise occurred in this filing; this is a compensation grant.

Context

This filing reports a standard executive equity grant (derivative award) meant for retention/compensation. Such awards do not involve immediate market purchases or sales and should be interpreted differently than open-market buys or disposals; they indicate compensation alignment rather than a direct bullish or bearish trading signal.